Overview

N6-methyladenosine (m6A) is the most abundant internal RNA modification, regulating RNA stability, splicing, translation, and decay. Dysregulation of m6A machinery is implicated in cancer, immune evasion, and neurological disorders. Our m6A Modification Detection Service provides comprehensive, high-resolution profiling to advance your epitranscriptomics research.

Our service combines multiple orthogonal approaches to detect m6A modifications across the transcriptome. We offer SELECT-m6A sequencing, a highly sensitive method that can detect low-abundance m6A sites critical for understanding disease mechanisms. Additionally, we employ nanopore direct RNA sequencing, enabling single-molecule resolution without the need for antibody enrichment or chemical conversion.

Using state-of-the-art computational tools such as m6Anet, a neural-network-based method, we achieve accurate identification and quantification of m6A from direct RNA sequencing data. This approach leverages multiple instance learning to distinguish m6A from unmodified bases, providing transcriptome-wide coverage in a single run.

Our end-to-end service includes sample preparation, library construction, sequencing, and bioinformatics analysis. We generate detailed reports with site-specific modification frequencies, differential methylation analysis, and functional annotation to support your research goals. Whether you are investigating immune evasion mechanisms or screening for drug targets, our platform delivers reliable data.

Advanced Technologies for Quantitative m6A Profiling

Explore Our Platform →

Multiple Detection Modalities for Flexible Experimental Design

Choose from a range of complementary m6A detection methods tailored to your sample type, throughput, and sensitivity requirements.

• SELECT-m6A Sequencing: A highly sensitive method that can detect low-abundance m6A modifications, making it suitable for identifying subtle changes in disease mechanisms or gene regulation.
• Nanopore Direct RNA Sequencing: Provides single-molecule resolution of m6A modifications across the transcriptome without the need for antibody enrichment or chemical conversion, enabling direct observation of modification patterns.
• Antibody-Based m6A Immunoprecipitation (MeRIP-seq): Widely used NGS-based method that enriches m6A-containing RNA fragments using an m6A-specific antibody, followed by high-throughput sequencing to identify modification sites.
• Enzymatic m6A Labeling (e.g., m6A-SEAL): An RNA modification enzyme-based fusion protein system that labels m6A sites for enrichment and detection, offering an alternative to antibody-based approaches.
• Crosslinking and Immunoprecipitation (miCLIP): Provides single-nucleotide resolution of m6A sites by combining UV crosslinking with antibody-based immunoprecipitation and sequencing.

Streamlined Workflow from Sample to Insight

Our established workflow ensures consistent, high-quality m6A detection across all projects.

• Sample Preparation and QC: Total RNA is extracted and subjected to rigorous quality control, including assessment of integrity, purity, and concentration. Ribosomal RNA depletion or poly(A) enrichment is performed as required.
• Library Construction: Depending on the chosen modality, libraries are prepared using SELECT-m6A, nanopore, or antibody-based protocols. Each method includes specific steps for m6A enrichment or direct detection.
• Sequencing: Libraries are sequenced on Illumina or Nanopore platforms to generate sufficient coverage for accurate m6A site identification and quantification. Sequencing depth is adjusted based on project requirements.
• Data Analysis and Reporting: Raw sequencing data are processed through our bioinformatics pipeline, including base calling, alignment, and m6A detection using tools like m6Anet. Results are compiled into a comprehensive report with modification frequencies, differential analysis, and functional annotations.

Project Milestones

Our project management ensures clear communication and timely delivery at each stage.

• Project Initiation: Consultation to define objectives, select detection modality, and confirm sample requirements.
• Sample Receipt and QC: Samples are received and subjected to quality control. RNA integrity and quantity are verified.
• Library Preparation and Sequencing: Libraries are constructed and sequenced according to the selected protocol. Data quality is monitored throughout.
• Bioinformatics Analysis: Sequencing data are processed through our m6A detection pipeline, including modification calling and differential analysis.
• Final Report Delivery: A comprehensive report is delivered with results, methods, and data files for further analysis.

Timelines are confirmed upon project initiation and depend on sample number, sequencing depth, and analysis complexity.

Rigorous Quality Control at Every Step

We implement multiple quality control checkpoints throughout the workflow to ensure data integrity and reproducibility. RNA integrity is assessed using Bioanalyzer or TapeStation, and only samples meeting high-quality thresholds proceed to library preparation.

Library quality is verified by quantitative PCR and fragment analysis before sequencing. During sequencing, base-calling quality scores and alignment rates are monitored. For nanopore data, we assess read length distribution and throughput.

Bioinformatics analysis includes extensive quality metrics such as coverage depth, modification calling confidence scores, and replicate reproducibility. All results are reviewed by a dedicated project scientist before delivery.

Why Choose Our m6A Detection Service

• Single-Molecule Resolution: Nanopore direct RNA sequencing provides transcriptome-wide m6A detection at single-molecule resolution, revealing modification patterns that are masked by bulk methods.
• Low-Abundance Detection: SELECT-m6A sequencing is specifically designed to detect low-abundance m6A modifications, enabling discovery of subtle changes relevant to disease mechanisms.
• Advanced Computational Tools: We utilize m6Anet, a neural-network-based method that leverages multiple instance learning for accurate m6A identification and quantification from direct RNA sequencing data.
• End-to-End Support: From experimental design through data analysis and reporting, our scientists provide dedicated support to ensure your project meets its objectives.
• Flexible Modalities: We offer a range of detection methods, including SELECT-m6A, nanopore, MeRIP-seq, and enzymatic approaches, allowing you to choose the best fit for your research question.

Compatible Sample Types

Our m6A detection service is compatible with a wide variety of biological samples, including but not limited to:

• Tissue: Fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue samples from various organs, including tumor samples.
• Cell Lines: Adherent and suspension cell lines, including primary cells, immortalized lines, and iPSC-derived cells.
• Whole Blood: Peripheral blood samples collected in RNA-stabilizing tubes for preservation of RNA integrity.
• Body Fluids: Plasma, serum, cerebrospinal fluid, and other biofluids for circulating RNA analysis.
• Microdissected Samples: Laser capture microdissected (LCM) samples for spatially resolved m6A profiling.

Contact Us

Whether you need genome-wide m6A profiling, targeted site validation, or quantitative modification analysis, our epitranscriptomics experts can help you select the right detection strategy and experimental design. Contact us today to discuss your project requirements.